Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 13/20 | 0.64 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KLK1 | P06870 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17546560 | 0.84 | KLKB1 (0.57) | KLKB1MLLT1TPSAB1L3MBTL1KLK1 | |
| SCHEMBL17540848 | 0.81 | KLKB1 (0.54) | KLKB1MLLT1TPSAB1L3MBTL1KLK1 | |
| SCHEMBL15874007 | 0.79 | KLKB1 (1.00) | KLKB1KLK1 | |
| SCHEMBL18924693 | 0.76 | KLKB1 (0.67) | KLKB1MLLT1TPSAB1 | |
| SCHEMBL30162870 | 0.76 | SMYD3 (0.57) | KLKB1SMYD3 | |
| SCHEMBL16566390 | 0.74 | SMYD3 (0.57) | KLKB1SMYD3 | |
| SCHEMBL17546583 | 0.73 | KLKB1 (0.60) | KLKB1MLLT1TPSAB1KLK1 | |
| SCHEMBL1829985 | 0.71 | L3MBTL1 (0.51) | KLKB1MLLT1L3MBTL1 | |
| SCHEMBL2943276 | 0.70 | L3MBTL1 (0.50) | KLKB1MLLT1L3MBTL1 | |
| SCHEMBL17540851 | 0.70 | KLKB1 (0.56) | KLKB1MLLT1TPSAB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | KLKB1 3/4885SMYD3 1159/4885MLLT1 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.